Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X9PF
|
||||
| Former ID |
DCL000074
|
||||
| Drug Name |
Bremelanotide
|
||||
| Synonyms |
Bremelanotide (USAN/INN)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Erectile dysfunction [ICD9: 302.72, 607.84; ICD10:F52.2, N48.4] | Phase 3 | [1] | ||
| Sexual dysfunction [ICD9: 302.7; ICD10:F52] | Phase 2a | [1] | |||
| Company |
Palatin Technol
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C50H68N14O10
|
||||
| Canonical SMILES |
CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=<br />O)C(NC1=O)CN2C=CN=C2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=C<br />C=CC=C54)C(=O)O)NC(=O)C
|
||||
| InChI |
1S/C50H68N14O10/c1-3-4-16-35(57-30(2)65)43(67)62-40-26-42(66)54-20-11-10-18-37(49(73)74)59-46(70)39(25-32-27-56-34-17-9-8-15-33(32)34)61-44(68)36(19-12-21-55-50(51)52)58-45(69)38(24-31-13-6-5-7-14-31)60-48(72)41(63-47(40)71)28-64-23-22-53-29-64/h5-9,13-15,17,22-23,27,29,35-41,56H,3-4,10-12,16,18-21,24-26,28H2,1-2H3,(H,54,66)(H,57,65)(H,58,69)(H,59,70)(H,60,72)(H,61,68)(H,62,67)(H,63,71)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
|
||||
| InChIKey |
CWPOKMRNYWXXLC-MFVUMRCOSA-N
|
||||
| CAS Number |
CAS 189691-06-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Melanocortin-4 receptor | Target Info | Agonist | [2], [3], [4] | |
| Melanocortin receptor | Target Info | Inhibitor | [5] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. Epub 2007 Aug 27. | ||||
| REF 2 | Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res. 2008 Jul;20 Suppl 1:S17-23. | ||||
| REF 3 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. | ||||
| REF 4 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. | ||||
| REF 5 | Wikipedia: Bremelanotide | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.